Skip to content
GCC AI Research

Search

Results for "MRSA"

KAUST and KACST join forces to prevent infectious diseases

KAUST ·

KAUST's Computational Bioscience Research Center (CBRC) and King Abdulaziz City for Science and Technology (KACST) have collaborated on research into methicillin-resistant Staphylococcus aureus (MRSA) within Saudi Arabia, starting in July 2018. The two-year project aims to understand MRSA drug resistance mechanisms specific to the Kingdom and its regions, with the goal of developing public health strategies. The project involves sequencing samples and performing bioinformatics analysis to support a network of researchers in the country. Why it matters: This initiative enhances Saudi Arabia's capacity to predict, prevent, and control infectious diseases, aligning with national health objectives and building local expertise in computational bioscience.

Portable COVID-19 test revolutionizes detection

KAUST ·

A KAUST-led team developed NIRVANA, a portable, briefcase-sized device for rapid detection and sequencing of SARS-CoV-2, influenza, and other viruses. The test utilizes isothermal recombinase amplification (RPA) and was validated on clinical samples and wastewater. NIRVANA can differentiate SARS-CoV-2 strains and doesn't require expensive infrastructure. Why it matters: This innovation enables rapid, decentralized virus detection and surveillance, crucial for pandemic response and monitoring new variants across the region.

Harnessing nanoparticles for COVID testing

KAUST ·

KAUST researchers are developing a streamlined COVID-19 diagnostic testing method using superparamagnetic nanoparticles (MNPs). The team, led by Assistant Professor Mo Li, aims to address reagent shortages and improve automation by creating an in-house extraction kit compatible with inactivated samples. Associate Professor Samir Hamdan identified a protocol for making silica-coated MNPs that survive inactivation reagents, enabling magnetic separation without centrifugation. Why it matters: This innovation could significantly increase testing capacity in Saudi Arabia and globally by reducing biosafety risks, reagent dependence, and manual processing.

KAUST partner SaudiVax advances treatment for COVID-19

KAUST ·

SaudiVax, located in the KAUST Research & Technology Park, is collaborating with the University of Pittsburgh and Merck France to develop a COVID-19 antibody injection. The antibody both protects against potential infection and neutralizes the virus in those already infected. SaudiVax is utilizing KAUST expertise and has contracted with Merck France for manufacturing since suitable facilities are not yet available in Saudi Arabia. Why it matters: This partnership highlights the growing biopharmaceutical capabilities in Saudi Arabia and the potential for KAUST to serve as a hub for medical innovation in the region.

Tough microbes found in NASA cleanrooms hold clues to space survival and biotech

KAUST ·

KAUST researchers in collaboration with NASA discovered 26 new bacterial species thriving in NASA cleanrooms. These species possess genetic traits that suggest they can survive the harsh conditions of space travel. The study analyzed the genetic traits of extremophiles to understand the risk of their transfer in space missions. Why it matters: This research supports Saudi Arabia's space vision and KAUST's role in microbial and space biology, aiding NASA in anticipating microorganisms encountered in space missions.

Early pathogen detection: Collaboration speeds up sensor development

KAUST ·

KAUST and King Faisal Specialist Hospital and Research Centre (KFSH&RC) are collaborating to develop bioelectronic sensors for rapid pathogen detection. These sensors aim to provide cheap and accurate results, potentially replacing conventional lab tests. A COVID-19 saliva test developed by KAUST researchers showed comparable sensitivity to PCR tests with a 15-minute turnaround. Why it matters: This partnership accelerates the development of novel diagnostic tools, which could improve healthcare accessibility in remote areas and low-income countries within the region.

Shining a light on the SARS-CoV-2 virus

KAUST ·

The KAUST Pathogen Genomics Laboratory (PGL), led by Professor Arnab Pain, is using DNA and RNA sequencing to study the SARS-CoV-2 virus. The lab is part of KAUST's Rapid Research Response Team (R3T), supporting Saudi healthcare stakeholders in combating COVID-19. Pain and his Ph.D. student Sharif Hala are partnering with the Saudi-CDC and Ministry of Health hospitals to sequence Saudi SARS-CoV-2 samples. Why it matters: This effort provides crucial data for understanding and monitoring the virus's spread and evolution within the Kingdom, informing public health strategies.

Using molecular microbiology to fight water scarcity and feed the world

KAUST ·

KAUST researchers have discovered that combining ultraviolet sunlight with phages increases the susceptibility of antibiotic-resistant bacteria to sunlight disinfection. This breakthrough addresses the growing threat of antimicrobial resistance, as the rate of discovering new antibiotics has slowed. The team demonstrated this method's effectiveness against a pathogenic E. coli strain found in Saudi wastewater. Why it matters: This research offers a promising alternative to traditional antibiotics, particularly relevant in regions like Singapore and the GCC where treated wastewater is a crucial water supply source.